• 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun M. Cancer Statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    Sekeres MA,Stone RM,Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004; 18: 809816.
  • 3
    Estey EH. How I treat older patients with AML. Blood. 2000; 96: 16701673.
  • 4
    Stone RM,Berg DT,George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995; 332: 16711677.
  • 5
    Kantarjian H,O'Brien S,Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106: 10901098.
  • 6
    Rees JK,Gray RG,Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol. 1996; 94: 8998.
  • 7
    Mayer RJ,Davis RB,Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896903.
  • 8
    Stone RM,Berg DT,George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001; 98: 548553.
  • 9
    Witz F,Sadoun A,Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998; 91: 27222730.
  • 10
    Lowenberg B,Zittoun R,Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 12681274.
  • 11
    Tilly H,Castaigne S,Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990; 8: 272279.
  • 12
    Menzin J,Boulanger L,Karsten V,Cahill A. Effects of initial treatment on survival among elderly AML patients: findings from the SEER-Medicare database. Blood. 2006; 108. Abstract 1973.
  • 13
    Sudan N,Rossetti JM,Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006; 107: 18391843.
  • 14
    Burnett AK,Milligan D,Prentice AG, et al. A comparison oflow-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109: 11141124.
  • 15
    Kantarjian HM,O'Brien S,Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007; 109: 11331137.
  • 16
    Mesa RA,Tefferi A,Li CY,Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia. 2006; 20: 20632064.
  • 17
    Bennett JM,Catovsky D,Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620625.
  • 18
    Vardiman JW,Harris NL,Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 22922302.
  • 19
    Byrd JC,Mrozek K,Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 43254336.
  • 20
    D'Agostino RBJr,D'Agostino RBSr. Estimating treatment effects using observational data. JAMA. 2007; 297: 314316.
  • 21
    LaLonde R. Evaluating the econometric evaluations of training programs. Am Econ Rev. 1986; 76: 604620.
  • 22
    Dehejia R,Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat. 2002; 84: 151161.
  • 23
    Estey E,Dohner H. Acute myeloid leukaemia. Lancet. 2006; 368: 18941907.
  • 24
    Sekeres MA,Peterson B,Dodge RK, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004; 103: 40364042.
  • 25
    Behringer B,Pitako JA,Kunzmann R, et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann Hematol. 2003; 82: 381389.
  • 26
    Frohling S,Schlenk RF,Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006; 108: 32803288.
  • 27
    Behl D,Porrata LF,Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006; 20: 2934.
  • 28
    Chen CC,Yang CF,Yang MH, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol. 2005; 16: 13661373.
  • 29
    Baer MR,George SL,Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002; 100: 12241232.
  • 30
    Appelbaum FR,Gundacker H,Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 34813485.
  • 31
    Hills R,Kell W,Burnett A. Treatment of AML in the elderly: who is “fit” for intensive chemotherapy? Blood. 2006; 108. Abstract 1974.